Introduction
Addressing an Unmet Need
Product Info
Pharmacological class
Clinical Studies
Menopausal Symptoms
FemarelleŽ & Bone Loss
    . Effect on Bone Mineral Density
    . Mechanism of action in the bone
    . Skeletal tissue & the uterus
    . Histology of skeletal tissue
FemarelleŽ & Breast Tissue
FemarelleŽ as a SERM
FAQ
Manufacturing Procedure

   
Addressing an Unmet Need

With the gradually increasing life expectancies of the world's populations, the number of menopausal women is growing dramatically. As a result, most women will live approximately one-third of their life span after menopause. This fact highlights the importance of menopause management that provides patients with better health and a higher quality of life.

 

The burden on physicians who care for this population has become significantly more complicated, because women not only live longer, but in modern societies they also remain active throughout their life.

 

With individuals now living longer, qualitative changes in their lives become much more relevant. This means that healthcare providers and physicians who treat peri- and post-menopausal women have to cope with the challenging concept of healthy aging.

 

A survey of the treatment options available to healthcare practitioners indicates that the main shortcoming of the available treatments relates to safety.

 

While today's women over the age of 50 expect a healthy and vibrant lifestyle, the quality of life can be dramatically impaired with the onset of menopause. This highlights the urgent need for a new generation of therapies capable of providing both the desired efficacy and the assurance of safety. These are the absolute criteria required for an acceptable treatment option that addresses both the short-term and the long-term consequences of menopause such as bone health.

 

Osteoporosis is largely preventable in most cases. Prevention is very important, because although there are various treatments for osteoporosis, there is currently no cure. Prevention of this disease demands long-term measures, which should be initiated when women reach menopause. Whether they suffer from menopausal symptoms or not, the decline in estrogen levels causes bone loss, which leads inevitably to osteopenia and the likelihood of sustaining osteoporotic fractures.

 

Femarelle® provides women with a safe and effective therapeutic option for the management of menopause; increasing quality of life, not only by providing fast-acting relief of menopausal symptoms, but also by protecting the bone from the bone loss process that follows menopause.

 
Home   Site Map   Disclamer © Se-cure Pharmaceuticals Ltd.